home / stock / mscl:cc / mscl:cc news

MSCL:CC News and Press, Satellos Bioscience Inc.

Stock Information
Company Name: Satellos Bioscience Inc.
Stock Symbol: MSCL:CC
Market: TSXVC
Website: satellos.com
Menu
MSCL:CC MSCL:CC Quote MSCL:CC Short MSCL:CC News MSCL:CC Articles MSCL:CC Message Board
Get MSCL:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
MSCL:CC - Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference

Interim observations from the Phase 2 TRAILHEAD study show continued improvement in handgrip strength, overall stability of elbow and shoulder strength in new dynamometry measurements Greater improvements in strength observed in participants with greater baseline muscle mass, further supporti...
MSCL:CC - Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will present two oral scientific presentations an...

MSCL:CC - Satellos to Host Virtual KOL Event on SAT-3247 in Duchenne Muscular Dystrophy

Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it will host a virtual key opinion leader (KOL) ev...

MSCL:CC - Satellos to Participate in Upcoming Investor Conferences

Satellos Bioscience Inc. (Nasdaq: MSLE , TSX: MSCL ) (“Satellos” or the “Company”), a clinical-stage biotechnology company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases, today announced that management will presen...
MSCL:CC - Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy

BASECAMP, a three-month, randomized, double-blind, placebo-controlled study, will evaluate SAT-3247’s safety and tolerability, and effect on muscle force, muscle quality and muscle regeneration Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” o...

MSCL:CC - Satellos to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Satellos Bioscience Inc. (Nasdaq: MSLE , TSX: MSCL ) (“Satellos” or the “Company”), a clinical-stage biotechnology company focused on restoring natural muscle repair and regeneration in degenerative muscle diseases, today announced that management will partic...

MSCL:CC - Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters' Option to Purchase Additional Shares

Satellos Bioscience Inc . (Nasdaq: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced that it has completed its previously-announced underwr...
MSCL:CC - Satellos prices $50M public offering

2026-02-06 09:00:17 ET More on Satellos Bioscience Inc. Satellos launches public offering, applies for Nasdaq listing Seeking Alpha’s Quant Rating on Satellos Bioscience Inc. Historical earnings data for Satellos Bioscience Inc. Financial information f...

MSCL:CC - Satellos Announces Pricing of US$50 Million Public Offering in Canada and the United States

BASE SHELF PROSPECTUS IS ACCESSIBLE, AND PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS ON SEDAR+ Satellos Bioscience Inc . (TSX: MSCL, Nasdaq: MSLE) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing lif...

MSCL:CC - Satellos launches public offering, applies for Nasdaq listing

2026-02-05 16:44:42 ET More on Satellos Bioscience Inc. Seeking Alpha’s Quant Rating on Satellos Bioscience Inc. Historical earnings data for Satellos Bioscience Inc. Financial information for Satellos Bioscience Inc. Read the full article on Seeking...
Next 10